EGFR and non-small cell lung carcinoma: Overall, this comprehensive investigation probed 18 study trials across 1852 Asian NSCLC clinical cases and 12 differing NSCLC therapies, including a range of EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib, together with EGFR- TKI/other chemotherapeutic agent combinatory therapies, such as gefitinib/lapatinib and gefitinib/pemetrexed treatment regimens [23].